Sleep Ventilation for Patients With Advanced Hypercapnic COPD

COPD Clinical Trial

Official title:

Implementation of a Precision Sleep Ventilation (PSV) Chronic Respiratory Failure Management Program for Patients With Advanced Hypercapnic COPD

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04210050
• Other study ID #: 2019P000778
• Status: Withdrawn
• Phase: N/A
• Start date: September 30, 2020
• Est. completion date: July 2026

Study information

• Verified date: January 2023
• Source: Beth Israel Deaconess Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Despite growing evidence showing benefit (in both clinical and cost standpoints), only a small percentage of COPD patients with chronic hypercapnic respiratory failure are managed with nocturnal ventilatory support. There is uncertainty of the value of aggressive nocturnal ventilation, especially polysomnographic estimation of therapy and home transcutaneous CO2 tracking.

The driving goal behind this project is to develop and implement a streamlined and comprehensive program for nocturnal ventilator management of patients with advanced, hypercapnic COPD.

Description:

The purpose of this protocol is to perform a prospective, randomized, comparative effectiveness clinical trial to evaluate the role of non-invasive nocturnal ventilation in addition to usual care, compared to usual care alone in the management of adult COPD patients with chronic hypercapnic respiratory failure. The study will focus on the primary end-points of time to hospital re-admission for acute exacerbation of COPD and/or an episode of acute on chronic hypercapnic respiratory failure, in addition to other clinically relevant outcomes including patient health-related quality of life, sleep quality indices, and gas exchange parameters. Approximately 300 BIDMC adult patients will be recruited and each patient monitored over a period of 12 months.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2026
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent prior to any study-mandated procedure.

2. Male or female aged = 18 years with advanced hypercapnic COPD

1. FEV1 = 50% predicted and

2. Prolonged hypercapnia during the daytime, at rest, without O2 or ventilatory support, PaCO2 > 52 mmHg on ABG (performed off of NIPPV), compensated with pH > 7.30

3. Willingness to use NIPPV treatment

4. English speaking

Women and minorities will be recruited in numbers reflecting representation in the Boston Metropolitan community which is approximately 84% Caucasian, 9% African American, 5% Hispanic American, and 2% Asian American, as the knowledge gained can apply to individuals of all ethnic background and gender.

We do not wish to limit our sample to a highly selected group of patients, to allow for more generalizable results.

Exclusion Criteria:

Subjects will be excluded from participation in the study for a history of:

• Significant sleep disordered breathing (AHI 4% = 15 events/hour) or high clinical suspicion (BMI = 35)

• Neuromuscular disease or other causes of hypoventilation

• Abnormalities of the thorax or lungs other than COPD

• Already treated with home NIPPV

• Unable to wean from ventilator during admission

• Unable to wean from NIPPV, pH < 7.30

• Recent tracheotomy decannulation

• History of severe depression or bipolar disorder requiring prior hospitalization or suicide attempts or ideation

• Cognitive impairment (such as advanced dementia) that would limit ability to provide consent or to use NIPPV

• Active recreational drug use

• Unstable housing that would limit ability to use NIPPV

• Severe heart failure (New York Heart Association stage IV)

• Active/unstable CAD

Related Conditions & MeSH terms

• COPD
• Hypercapnia

Intervention

Device:
• Home noninvasive nocturnal ventilation with Breas VIVO 50 home ventilator or newer model as available, Breas Medical.
In the usual care plus NIPPV group, those able to undergo attended PSG will be titrated with volume targeted pressure support mode, aiming to lower the baseline TcCO2 by 10 mmHg. In some cases, the CO2 cannot be lowered by that amount on a single titration, but rather will decrease over time. For those unable to undergo lab titration (too frail, no transportation, decline/refuse), NIPPV will be initiated with empiric settings based on nighttime home CO2 tracking and daytime ABG monitoring.

Diagnostic Test:
• Arterial blood gas (ABG) and serum bicarbonate level
Will be obtained at baseline (before randomization), then at 3, 6 and 12 months into the study
• Overnight home oximetry and transcutaneous CO2 monitoring
will be conducted at 1 and 6 months into the study (for subjects in the NIPPV plus usual care group, testing will be done while using the ventilator.

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Beth Israel Deaconess Medical Center	Breas Medical S.A.R.L.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Ambulatory BP profiles	In a subset of subjects (from usual care and usual care plus ventilation groups), 24-hour ambulatory BP monitoring will be conducted (at baseline and after 3 months) to assess for change in 24-hour and nocturnal systolic, diastolic and mean BPs.	3 months compared to baseline
Other	Inflammatory biomarkers	High sensitivity C-reactive protein [hs-CRP], units mg/ml, can be measured from peripheral blood. Elevated levels reflect increased systemic inflammation. Studies have shown that individuals with elevated levels (above 2 mg/ml) are at increased risk of cardiovascular disease. During this trial, HR-CRP will be obtained at baseline and after 3 and 12 months in subjects to assess whether there is a favorable change in subjects treated with nocturnal ventilation + usual care, as compared to usual care.	3 and 12 months compared to baseline
Primary	Time to readmission or death	time to re-admission for acute exacerbation of COPD and/or acute on chronic hypercapnic respiratory failure or death	within 12 months
Secondary	Patient health related quality of life (HRQOL)	The RAND SF-36, a 36-question multiple choice QOL form will be used to assess general health perception. The questions target eight health domains or scales: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal/emotional problems, emotional well-being, social functioning, energy/fatigue, general health perceptions, and one's perceived change in health.; There is a 2-step process used in scoring, such that the score for each of the scales represent the average for all item in the scale that were answered. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Next, items in the same scale are averaged together to create 8 scale scores. The lower the score the more disability and the higher the score the less disability.; Scores will be assessed at baseline, 3 and 12 months for usual care and usual care plus ventilation support for all subjects.	12 months
Secondary	Dyspnea scale	change in results of the Medical Research Council dyspnea scale, a categorical scale from 1-5, higher score =more limitation on daily activity due to breathlessness. Scores will be assessed at baseline, 3 and 12 months for usual care and usual care plus ventilation subjects.	12 months
Secondary	Gas exchange	Change in CO2 from ABG and serum bicarbonate	12 months
Secondary	General health status	St. George's Respiratory questionnaire, a 50 item questionnaire that measures health status in patients with COPD will be completed at baseline, and after 3 and 12 months in all subjects. For this questionnaire, a score of 0 = best QOL, and a score of 100 = worst QOL. The questions focus on three areas - symptoms, activity, and impact (psycho-social).	12 months